FDA OKs First Targeted Treatment for HER2-Positive Colorectal Cancer

(MedPage Today) -- The FDA has granted accelerated approval to tucatinib (Tukysa) in combination with trastuzumab (Herceptin) for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer who have progressed...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news